Spigelman staging (FAP duodenal adenoma burden)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-DUODENAL-ADENOMA-SPIGELMAN-SCORE |
|---|---|
| Type | Biomarker |
| Aliases | FAP duodenal stageSpigelman classificationSpigelman score for duodenal polyposisduodenal polyposis stagingСтадіювання за Spigelman (тягар дуоденальних аденом при FAP) |
| Status | reviewed 2026-05-18 |
| Diseases | None declared |
| Sources | SRC-NCCN-COLON-2025 |
Biomarker Facts
| Biomarker type | clinical_composite |
|---|---|
| Measurement | MethodComposite endoscopic + histologic score from duodenoscopy biopsies: (1) polyp number, (2) max polyp size, (3) histology, (4) dysplasia grade. Each scored 0-3 → stage 0 (sum 0), I (1-4), II (5-6), III (7-8), IV (9-12) Unitscategorical Spigelman stage: 0 | I | II | III | IV |
| Related biomarkers | BIO-APC |
Notes
STUB. Standard staging for duodenal adenomatosis in FAP/MUTYH-associated polyposis. Drives surveillance interval and intervention: stage I-II every 2-5 y; stage III every 6-12 mo + endoscopic ablation; stage IV → referral for prophylactic pancreas-preserving duodenectomy (lifetime duodenal cancer risk ~5-10% overall, ~36% at stage IV). Updated 2017 Mayo classification adds ampullary criteria — captured in notes per authoring locality.
Used By
No reverse references found in the YAML corpus.